The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC).
 
Rafee Talukder
No Relationships to Disclose
 
Dimitra Rafailia Bakaloudi
No Relationships to Disclose
 
Genevieve Ihsiu Lin
No Relationships to Disclose
 
Tom Enright
No Relationships to Disclose
 
Jacob Beck Leary
No Relationships to Disclose
 
Dimitrios Makrakis
No Relationships to Disclose
 
Nishita Tripathi
No Relationships to Disclose
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
 
Tanya Jindal
No Relationships to Disclose
 
Vadim S Koshkin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - Clovis Oncology; Endocyte (Inst); Merck (Inst); Nektar (Inst); Taiho Oncology (Inst)
 
Jason R Brown
Honoraria - AstraZeneca
Speakers' Bureau - EMD Serono
Research Funding - Bicycle Therapeutics (Inst); Jounce Therapeutics (Inst); Merck (Inst); Novita Pharmaceuticals (Inst); Seagen (Inst)
 
Jeffrey Johnson
No Relationships to Disclose
 
Yousef Zakharia
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb/Medarex; Cardinal Health; Castle Biosciences; Clovis Oncology; Eisai; EMD Serono; Exelixis; Janssen; Myovant Sciences; Novartis; Pfizer; Roche/Genentech; Seagen; TTC Oncology
Research Funding - Eisai (Inst); Exelixis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Newlink Genetics
 
Joseph J. Park
No Relationships to Disclose
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; BMS; Merck; Pfizer
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; Merck
 
Rafael Morales Barrera
No Relationships to Disclose
 
Alexandra Drakaki
Employment - ATHOS THERAPEUTICS (I); ATTICA SCIENCES (I); Dyania Health (I)
Leadership - ATHOS THERAPEUTICS (I); ATTICA SCIENCES (I)
Stock and Other Ownership Interests - Alimera Sciences (I); Athos Therapeutics (I); ATTICA SCIENCES; Dyania Health (I); Kyn therapeutics (I); Moderna Therapeutics (I); PROTEAS BIOANALYTICS (I); Urogen pharma (I)
Consulting or Advisory Role - AstraZeneca; AVEO; Bristol-Myers Squibb; DYANIA HEALTH; Exelixis; Janssen; Merck; PACT Pharma; RADMETRIX; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); BMS (Inst); Genentech/Roche (Inst); Immunomedics/Gilead (Inst); Infinity Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Kite/Gilead; Merck Sharp & Dohme (Inst); Seattle Genetics/Astellas (Inst)
Patents, Royalties, Other Intellectual Property - My significant other has several patents with UCLA, Harvard Medical School, Athos Therapeutics, Proteas Bioanalytics and ATTICA Sciences (I)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Seagen
 
Pedro C. Barata
Honoraria - UroToday
Consulting or Advisory Role - AstraZeneca; AVEO; Bayer; BMS; Caris Life Sciences; Dendreon (Inst); Eisai; EMD Serono; Exelixis; Pfizer
Speakers' Bureau - AstraZeneca; Bayer (Inst); Caris Life Sciences (Inst); Pfizer/Astellas (Inst)
Research Funding - AVEO (Inst); Blue Earth Diagnostics (Inst); Merck (Inst); Pfizer (Inst)
 
Ali Raza Khaki
Honoraria - HMP; OncLive/MJH Life Sciences
Consulting or Advisory Role - Gilead Sciences (Inst)
Other Relationship - Tempus
(OPTIONAL) Uncompensated Relationships - Janssen; Seattle Genetics/Astellas
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; AADi; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; CG Oncology; Dyania Health; EMD Serono; Exelixis; Fresenius Kabi; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; ImmunityBio; Janssen; Lucence; Merck; Mirati Therapeutics; Pfizer; PureTech; QED Therapeutics; Regeneron; Roche; Seagen; Silverback Therapeutics; Strata Oncology; Urogen pharma
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)